Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Reduced Appetite in Crohn's Disease: The Role of the Brain in the Control of Food Intake

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02772458
Recruitment Status : Completed
First Posted : May 13, 2016
Last Update Posted : April 17, 2019
Sponsor:
Information provided by (Responsible Party):
University of Nottingham

Brief Summary:
Crohn's disease (CD) is becoming more common, specifically in the western world. One of the main features of this disease is weight loss and malnutrition. Although clinically common, these problems are not well understood. Loss of appetite and symptoms such as tummy aches and bloating are common causes for weight loss in this group of patients. This problem has a strong negative effect on the patients' quality of life and significantly increases the cost of treating CD. Enteroendocrine cells are nutrient sensors in the bowel that relay to the brain to control food intake. Recent evidence has showed that these cells increase in number in active CD and secrete more hormones that negatively affect appetite. The increased levels of these hormones should have an overall negative effect on the brain and thus decrease food intake, bloating, symptoms of sickness. All these symptoms lead to malnutrition. These are hypotheses that require further proof. Current technological advances in magnetic resonance imaging (MRI) has enabled the mapping of changes in activity in important areas in the brain that control food intake. The involvement of the brain in control of food intake is still not fully understood. This work will be the first step in the right direction to start targeting the problems of appetite, weight loss and a poor quality of life.

Condition or disease Intervention/treatment Phase
Crohn's Disease Other: Dodecanoate acid and saline Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 80 participants
Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: Single (Participant)
Primary Purpose: Basic Science
Official Title: Reduced Appetite in Crohn's Disease: Investigating the Role of the Gut Brain Pathways
Study Start Date : June 2015
Actual Primary Completion Date : September 2018
Actual Study Completion Date : September 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Crohn's Disease

Arm Intervention/treatment
Experimental: Crohn's Disease
Active Crohn's Disease
Other: Dodecanoate acid and saline
Test drink

Experimental: Healthy
Healthy volunteers
Other: Dodecanoate acid and saline
Test drink




Primary Outcome Measures :
  1. Changes in Blood Oxygenation Level Dependent (BOLD) response in the brain following a fatty acid test meal in Crohn's patients and healthy controls [ Time Frame: 3 years ]

Secondary Outcome Measures :
  1. Changes in arterial spin labeling measures of cerebral blood flow and changes in gut peptide levels following the fatty acid test meal. [ Time Frame: 3 years ]

    The increase or decrease in BOLD signal of the brain following the fatty acid stimuli will be correlated to the gut peptide levels which are listed as follows:

    1. CCK (pmol/ml)
    2. GLP-1 (pM)
    3. PYY (pg/ml)
    4. Ghrelin (ng/ml)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   16 Years to 75 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Age 16-75 years
  2. Ulceration seen at ileocolonoscopy, aiming for a simple endoscopic score for Crohn's disease (SES-CD) of 4-19, in the absence of stricturing disease or,
  3. Intestinal inflammation or deep ulceration seen on CT or MR enterography, with the disease activity quantified via the MaRIA score or,
  4. Faecal calprotectin of >250µg/g
  5. C-Reactive protein >5mg/dl
  6. Harvey-Bradshaw index score of 5-16
  7. Body mass index (BMI) 18-35
  8. As for HV participants, inclusion criteria 1 and 7 will apply.

Exclusion Criteria:

  1. Malignant disease
  2. BMI <18 and >35
  3. Significant cardiovascular or respiratory disease
  4. Diabetes mellitus
  5. Current Infection
  6. Neurological or cognitive impairment; significant physical disability
  7. Significant hepatic disease or renal failure
  8. Abnormal blood results other than those explained by CD including bleeding diatheses (apart from in the case of HV where all unexplained blood results are an exclusion criteria)
  9. Subjects currently participating in (or in the last three months) any other research project
  10. pregnancy or breastfeeding or
  11. if MRI is contraindicated (e.g. pacemaker).
  12. Severe Crohn's disease where a delay in a change in medical treatment for 23 weeks would not be clinically advisable.
  13. As for healthy volunteer participants all exclusion criteria apart from no.12.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02772458


Locations
Layout table for location information
United Kingdom
University of Nottingham
Nottingham, United Kingdom, NG7 2RD
University of Nottingham
Nottingham, United Kingdom
Sponsors and Collaborators
University of Nottingham
Layout table for additonal information
Responsible Party: University of Nottingham
ClinicalTrials.gov Identifier: NCT02772458    
Other Study ID Numbers: 14038
First Posted: May 13, 2016    Key Record Dates
Last Update Posted: April 17, 2019
Last Verified: October 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by University of Nottingham:
Crohn's Disease
gut brain axis
reduced appetite
Additional relevant MeSH terms:
Layout table for MeSH terms
Crohn Disease
Inflammatory Bowel Diseases
Gastroenteritis
Gastrointestinal Diseases
Digestive System Diseases
Intestinal Diseases